Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing

DSpace/Manakin Repository

Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing

Citable link to this page

 

 
Title: Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Author: Ding, Q.; Strong, A.; Patel, K. M.; Ng, S.-L.; Gosis, Bridget Stephanie; Regan, Stephanie N.; Cowan, Chad A.; Rader, D. J.; Musunuru, Kiran

Note: Order does not necessarily reflect citation order of authors.

Citation: Ding, Q., A. Strong, K. M. Patel, S.-L. Ng, B. S. Gosis, S. N. Regan, C. A. Cowan, D. J. Rader, and K. Musunuru. 2014. “Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing.” Circulation Research 115 (5) (June 10): 488–492. doi:10.1161/circresaha.115.304351.
Full Text & Related Files:
Abstract: Rationale: Individuals with naturally occurring loss-of-function proprotein convertase subtilisin/kexin type 9 (PCSK9) mutations experience reduced low-density lipoprotein cholesterol levels and protection against cardiovascular disease.

Objective: The goal of this study was to assess whether genome editing using a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated system can efficiently introduce loss-of-function mutations into the endogenous PCSK9 gene in vivo.

Methods and Results: We used adenovirus to express CRISPR-associated 9 and a CRISPR guide RNA targeting Pcsk9 in mouse liver, where the gene is specifically expressed. We found that <3 to 4 days of administration of the virus, the mutagenesis rate of Pcsk9 in the liver was as high as >50%. This resulted in decreased plasma PCSK9 levels, increased hepatic low-density lipoprotein receptor levels, and decreased plasma cholesterol levels (by 35–40%). No off-target mutagenesis was detected in 10 selected sites.

Conclusions: Genome editing with the CRISPR–CRISPR-associated 9 system disrupts the Pcsk9 gene in vivo with high efficiency and reduces blood cholesterol levels in mice. This approach may have therapeutic potential for the prevention of cardiovascular disease in humans.
Published Version: doi:10.1161/circresaha.115.304351
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134749/
Terms of Use: This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:20487897
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters